project id: TCGA-UCEC; case submitter id: TCGA-BK-A6W3; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.83; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.76; rna integrity number: 8.1; age at index: 34; days to birth: -12590; ethnicity: not hispanic or latino; gender: female; race: black or african american; vital status: Alive; year of birth: 1979; age at diagnosis: 12590; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 305.0; figo stage: Stage II; icd 10 code: C54.1; last known disease status: not reported; morphology: 8380/3; primary diagnosis: Endometrioid adenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Endometrium; synchronous malignancy: No; tissue or organ of origin: Endometrium; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 94; days to sample procurement: 0; initial weight: 150.0; portion submitter id: TCGA-BK-A6W3-01A-12; percent lymphocyte infiltration: 5.0; percent monocyte infiltration: 1.0; percent necrosis: 0.0; percent neutrophil infiltration: 1.0; percent normal cells: 10.0; percent stromal cells: 10.0; percent tumor cells: 80.0; percent tumor nuclei: 80.0;